Baseline patient characteristics
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 61 (38-83) |
| Male sex, no. (%) | 16 (73) |
| MF type, no. (%) | |
| Primary | 15 (68) |
| Post-PV | 4 (18) |
| Post-ET | 3 (14) |
| Time from diagnosis, mo | 28 (2-184) |
| No. of prior therapies | 3 (0-6) |
| Patients previously untreated | 2 (9) |
| Hemoglobin, g/dL | 9.7 (6.9-15.8) |
| WBC, × 109/L | 13.3 (1.3-62.2) |
| Platelets, × 109/L | 135 (14-1328) |
| Transfusion dependency | 8 (36) |
| Splenomegaly | 18 (90)* |
| Spleen size, cm from left costal margin | 19 (0-30) |
| JAK2V617F/total JAK2 ratio, percentage | 53.5 (13.5-96.6) |
| Abnormal cytogenetics | 14 (64) |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 61 (38-83) |
| Male sex, no. (%) | 16 (73) |
| MF type, no. (%) | |
| Primary | 15 (68) |
| Post-PV | 4 (18) |
| Post-ET | 3 (14) |
| Time from diagnosis, mo | 28 (2-184) |
| No. of prior therapies | 3 (0-6) |
| Patients previously untreated | 2 (9) |
| Hemoglobin, g/dL | 9.7 (6.9-15.8) |
| WBC, × 109/L | 13.3 (1.3-62.2) |
| Platelets, × 109/L | 135 (14-1328) |
| Transfusion dependency | 8 (36) |
| Splenomegaly | 18 (90)* |
| Spleen size, cm from left costal margin | 19 (0-30) |
| JAK2V617F/total JAK2 ratio, percentage | 53.5 (13.5-96.6) |
| Abnormal cytogenetics | 14 (64) |
Two patients had prior splenectomy.